• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KALV

    KalVista Pharmaceuticals Inc.

    Subscribe to $KALV
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: kalvista.com

    Peers

    $BCRX
    $VRNA

    Recent Analyst Ratings for KalVista Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    1/31/2025$19.00Mkt Outperform
    JMP Securities
    1/7/2025$30.00Buy
    TD Cowen
    12/18/2024$22.00Buy
    BofA Securities
    3/11/2022$48.00 → $42.00Buy
    Needham
    12/10/2021$50.00 → $48.00Buy
    Needham
    See more ratings

    KalVista Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with t

      5/2/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a

      4/30/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

      -Up to $24 million in upfront and milestone payments, plus royalties- -Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity- -Kaken brings regional expertise and proven track record in commercializing innovative therapies- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: 4521.T) for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). KalVista will receive an upfront payment of $11 million, with an additional payment o

      4/8/25 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 87,000 shares of KalVista common stock on April 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with t

      4/2/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is se

      3/31/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

      Initial target enrollment surpassed in fewer than seven months; trial expanded due to high demand First data presentation expected before year-end; sNDA submission by mid-2026 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel, oral plasma kallikrein inhibitor, in pediatric patients between the ages of two and 11 with hereditary angioedema (HAE). "We're proud to share that we achieved target enrollment in our KONFIDENT-KID trial a full year ahead of schedule and expanded the trial size due to overwhelming interest," said Ben Palleiko, CEO of KalVista. "The high

      3/25/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

      –Announced seventh regulatory application submission and secured orphan drug designation for sebetralstat in Japan for hereditary angioedema– – Presented new data that showed effectiveness of sebetralstat to address critical unmet needs in laryngeal attacks, adolescents with HAE and patients experiencing attacks despite long-term prophylaxis (LTP)– –Will host virtual investor day to discuss commercialization strategy ahead of June PDUFA– KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today released financial results for the third fiscal quarter ended January 31, 2025, and provided an operational update. "Sebetralstat is poised to be the first and only oral on-demand treatment for HAE, wi

      3/12/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

      Webcast scheduled for Tuesday, March 25 at 8:00 am ET KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company's investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here. In addition to presentations by KalVista's management team, leading external experts in HAE will discuss the current treatment guidelines and unmet needs for people living with HAE, and how sebetralstat could provide a new treatment option. A live question-and-

      3/10/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the compensation committee of KalVista's board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on March 3, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with

      3/4/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

      –Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief– –Pooled data analysis showed adolescents treated with sebetralstat in median 4 minutes compared to over 3 hours in surveys – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. "The growing body of data from the KONFIDENT-S study consistently

      3/3/25 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 4:00:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 3:57:49 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

      SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/14/24 12:02:33 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

      SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/13/24 12:54:34 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/12/24 4:05:37 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/12/24 9:31:11 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by KalVista Pharmaceuticals Inc.

      SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/7/24 2:34:57 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KalVista Pharmaceuticals Inc.

      SC 13G/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      11/4/24 12:00:37 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by KalVista Pharmaceuticals Inc. (Amendment)

      SC 13D/A - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      4/1/24 4:14:49 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KalVista Pharmaceuticals Inc.

      SC 13G - KalVista Pharmaceuticals, Inc. (0001348911) (Subject)

      2/26/24 4:35:48 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. SEC Filings

    See more
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      4/8/25 7:30:22 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by KalVista Pharmaceuticals Inc.

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/17/25 4:01:13 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/12/25 4:41:06 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

      10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      3/12/25 4:31:45 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by KalVista Pharmaceuticals Inc.

      S-8 - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      1/16/25 4:57:31 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      12/16/24 7:07:31 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      12/5/24 4:17:12 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by KalVista Pharmaceuticals Inc.

      10-Q - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      12/5/24 4:07:19 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      11/26/24 7:06:01 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

      8-K - KalVista Pharmaceuticals, Inc. (0001348911) (Filer)

      11/4/24 4:40:30 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      JMP Securities initiated coverage of KalVista Pharmaceuticals with a rating of Mkt Outperform and set a new price target of $19.00

      1/31/25 7:03:28 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on KalVista Pharmaceuticals with a new price target

      TD Cowen initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      1/7/25 7:55:33 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on KalVista Pharmaceuticals with a new price target

      BofA Securities initiated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/18/24 7:36:39 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

      Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $42.00 from $48.00 previously

      3/11/22 5:13:42 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

      Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $50.00 previously

      12/10/21 5:40:35 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink resumed coverage on KalVista Pharmaceuticals

      SVB Leerink resumed coverage of KalVista Pharmaceuticals with a rating of Buy

      3/16/21 7:41:07 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on KalVista Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

      2/25/21 10:44:10 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on KalVista Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

      2/18/21 8:36:48 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital reiterated coverage on KalVista Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $55.00 from $30.00 previously

      2/17/21 8:12:55 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on KalVista Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $48.00 from $30.00 previously

      2/10/21 6:13:44 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • KalVista Appoints Jeb Ledell as Chief Operating Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. "I am pleased to welcome Jeb to KalVista at this key time in our evolution. His extensive experience in leading teams and driving efficiency within companies like ours makes him a valued addition to the team as we continue to evolve into a commercial entity," said Ben Palleiko, Chief Executive Officer of KalVista. "I am confident that his proven skills will help us to achieve our goal of delivering s

      12/16/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company's Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. "I am pleased to welcome Dr. Reid, with his deep expertise in high-growth biotech companies, to the KalVista Board of Directors," said Ben Palleiko, Chief Executive Officer of KalVista. "His extensive biopharmaceutical and strategic experience will be a tremendous asset as the Company continues to progress sebetralstat towards global market approval and commercialization." "I am excited to join the KalVist

      11/26/24 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Appoints Brian Piekos as Chief Financial Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. "Brian's deep industry experience and expertise in managing financial and capital strategies makes him a strong addition to KalVista as we prepare for the commercialization of sebetralstat," said Ben Palleiko, Chief Executive Officer at KalVista. "I'm excited to welcome Brian to KalVista, as he shares our commitment to patients and a results-driven approach to business excellence." "I am excited to join

      9/10/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company's Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a business leader with significant experience building markets and launching novel therapeutics to treat specialty and rare/orphan diseases. "We welcome Bill to our Board of Directors," said Ben Palleiko, CEO of KalVista. "His experience in commercial and me

      4/22/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

      - Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024. "This has been an exciting and busy period for KalVista, as we achieved key milestones with the release of our phase 3 KONFIDENT data and th

      3/11/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

      – Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that Benjamin L. Palleiko, the Company's current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately. In conjunction, Andrew Crockett has submitted his resignation as CEO and a director of the Company. This appointment is the result of a planned tr

      3/7/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief Commercial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230725517894/en/KalVista Chief Commercial Officer Nicole Sweeny (Photo: Business Wire) "As KalVista prepares for our evolution into a commercial organization, we continue to strategically add individuals with deep experience in hereditary angioedema (HAE) product launches and global commercialization," said Andrew Cro

      7/25/23 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman

      – Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that the Board of Directors has appointed current member Brian J.G. Pereira, M.D., as Chairman, effective immediately. In conjunction, current Chairman Martin Edwards, M.D. has resigned from the Board in a planned transition concurrent with the Company's annual meeting. "We are pleased that Brian has agreed to take the Chairman role at this critical time," said Andrew Crockett, Chief Executive Officer of K

      10/17/22 6:45:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

      – Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2022. "We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise," said Andrew Crockett, Chief Executive Officer of KalVista. "We are me

      7/7/22 6:45:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

      KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005196/en/KalVista CMO Paul Audhya (Photo: Business Wire) "As we advance our oral hereditary angioedema franchise in the clinic, KalVista will be strategically growing by adding individuals with deep experience in late-stage drug development and global commercialization," said Andrew Crockett, Chief Executive O

      5/3/21 7:00:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 15,625 shares and sold $79,828 worth of shares (6,669 units at $11.97), increasing direct ownership by 3% to 287,811 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      3/10/25 6:43:21 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $23,988 worth of shares (2,394 units at $10.02), increasing direct ownership by 3% to 102,940 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:37:22 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Palleiko Benjamin L

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:36:38 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $19,218 worth of shares (1,918 units at $10.02), increasing direct ownership by 1% to 93,952 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:36:14 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Piekos Brian

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/25/25 8:35:13 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 4,204 shares and sold $25,553 worth of shares (2,601 units at $9.82), increasing direct ownership by 2% to 92,745 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/19/25 8:47:31 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,447 shares and sold $30,701 worth of shares (3,125 units at $9.82), increasing direct ownership by 3% to 100,334 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/19/25 8:46:58 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 9,363 shares and sold $50,143 worth of shares (5,104 units at $9.82), increasing direct ownership by 2% to 278,855 units (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/19/25 8:46:26 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/14/25 7:45:15 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      4/11/25 5:22:07 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/14/25 7:45:15 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/11/25 7:51:08 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $621,628 worth of shares (70,023 units at $8.88) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/3/25 7:42:00 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $1,257,829 worth of shares (86,048 units at $14.62) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/8/24 8:11:37 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $1,274,793 worth of shares (88,099 units at $14.47) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      2/1/24 4:38:43 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $1,289,802 worth of shares (91,804 units at $14.05) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      1/29/24 7:07:16 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $1,241,685 worth of shares (99,129 units at $12.53) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      1/24/24 8:24:01 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $1,801,602 worth of shares (143,605 units at $12.55) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      1/19/24 6:02:25 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Venrock Healthcare Capital Partners Iii, L.P. bought $333,779 worth of shares (26,246 units at $12.72) (SEC Form 4)

      4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

      1/16/24 7:04:01 PM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    KalVista Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

      – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss trial results today at 8:30 a.m. ET – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat as oral on-demand therapy for hereditary angioedema (HAE). KONFIDENT was the l

      2/13/24 6:30:00 AM ET
      $KALV
      Biotechnology: Pharmaceutical Preparations
      Health Care